This is likely a controversial observation yet could some of the push back, or market neglect, of Clinuvel that is keeping its SP down, be due to it being seen as a solution aimed at a particular ethnic group, one that has historically faced some difficulties getting support in some parts of the medical community, and market, for unique medical solutions.
I just tend to notice that when Clinuvel presents high-quality and well received presentation like this one rather than an uptick in market approval the result is muted, well presentations emphasising its EPP product line which is less specific to ethnic groups seem to initially get a better market reception.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)